In a major step to ensure accessible and affordable healthcare, Kuwait’s Minister of Health, Dr. Ahmed Al-Awadhi, has approved price reductions for 544 medicines and pharmaceutical products by up to 78.5%—now the lowest in the Gulf Cooperation Council (GCC). Additionally, a new pricing list has been set for 144 medicines, also ranking them as the most cost-effective in the region.
The reductions cover critical treatments, including medications for cancer, diabetes, blood pressure, cholesterol, asthma, and chronic conditions like arthritis and inflammatory bowel diseases. Notably, tirzepatide (Mounjaro) injections saw a 30% price drop starting today, following Ministerial Resolution No. 92 of 2025. Other key reductions include Wegovy (37.3% cheaper) and Saxenda (20.8% cheaper), supporting diabetes and obesity patients.
The ministry stated that these measures align with Kuwait’s national policy to enhance healthcare affordability, regularly review drug pricing, and monitor pharmaceutical markets to ensure fair access for citizens and residents.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Velit omnis animi et iure laudantium vitae, praesentium optio, sapiente distinctio illo?